Wednesday, July 8, 2026

Drug profile · INN

triamterene

triamterene (TRIAMTERENE) is a amiloride-sensitive sodium channel, enac blocker. Route of administration: oral. Current US regulatory status: approved.

FDA: approved
US status approved
Patents linked 0
Pipeline programs 0
News articles 0
Drug details — triamterene
US status
approved
Class
Route
ORAL
Patents
0
Programs
0
Data quality
0.84

Quick answer

triamterene (TRIAMTERENE) is a amiloride-sensitive sodium channel, enac blocker. Route of administration: oral. Current US regulatory status: approved.

Key facts

INN triamterene
Brand TRIAMTERENE
Mechanism Amiloride-sensitive sodium channel, ENaC blocker
Target Amiloride-sensitive sodium channel, ENaC
Route ORAL
Formulation CAPSULE

Mechanism of action

Amiloride-sensitive sodium channel, ENaC blocker

Primary target: Amiloride-sensitive sodium channel, ENaC

Approval history

Authority Status Date
FDA approved

Related & competitor drugs

  1. amiloride hydrochloride Amiloride-sensitive sodium channel, ENaC blocker

Frequently asked questions

What is triamterene?

triamterene (TRIAMTERENE) is a amiloride-sensitive sodium channel, enac blocker. Route of administration: oral. Current US regulatory status: approved.

What is the brand name for triamterene?

TRIAMTERENE is a marketed brand name for triamterene. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of triamterene?

triamterene has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.